Becton, Dickinson and Company delivered a Q1 2026 earnings beat, with $2.91 non-GAAP EPS and $5.25B revenue, surpassing ...

Seniors from Sand Creek High School conducted blood draws on volunteers on Thursday, Feb. 5, as they prepare for a national ...

Becton, Dickinson and Company (NYSE:BDX) Q1 2026 Earnings Call Transcript February 9, 2026 Becton, Dickinson and Company beats earnings expectations. Reported EPS is $2.91, expectations were $2.81.

Correspondence to: Professor Martin Schwellnus University of Cape Town, UCT/MRC Research Unit for Exercise Science and Sports Medicine, Department of Human Biology, Faculty of Health Sciences, ...

Introduction: The automated counting of reticulocytes has some advantages over the manual method routinely used in clinical laboratories. Technological innovations provide more statistically reliable ...

Rectal temperature, heart and respiratory rates, and the course of some blood parameters were monitored in calves during perinatal and neonatal periods. The study was carried out on eight Limousine ...

As a reminder, beginning October 1, we began operating under our previously disclosed new Becton, Dickinson and Company ...

Medical essentials segment sales were up 0.6% (-0.6% FXN) to $1.595 billion. BioPharma Systems’ sales of $429 million were up 2.7% (+1% FXN), driven by double-digit growth in Biologics, partially ...

Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXNNew BD revenue increased 2.5% FXNGAAP and adjusted diluted EPS of $1.34 and $2.91, ...

Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXN New BD revenue increased 2.5% FXN GAAP and adjusted diluted EPS of $1.34 and $2.91, respectively Combination ...